BidaskClub upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a buy rating in a research report sent to investors on Friday morning.

A number of other research analysts also recently commented on the company. ValuEngine upgraded Corcept Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 30th. Zacks Investment Research downgraded Corcept Therapeutics from a hold rating to a sell rating in a research report on Thursday, September 13th. Stifel Nicolaus restated a hold rating and issued a $11.00 price target (down from $20.00) on shares of Corcept Therapeutics in a research report on Friday, August 10th. B. Riley lowered their price target on Corcept Therapeutics from $30.00 to $22.00 and set a buy rating for the company in a research report on Monday, August 13th. Finally, Cantor Fitzgerald started coverage on Corcept Therapeutics in a research report on Thursday, August 23rd. They issued a neutral rating and a $17.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $21.83.

Shares of NASDAQ CORT traded down $0.68 during midday trading on Friday, reaching $12.24. 1,643,057 shares of the stock traded hands, compared to its average volume of 1,484,093. The company has a market capitalization of $1.63 billion, a P/E ratio of 27.82 and a beta of 1.62. Corcept Therapeutics has a one year low of $11.55 and a one year high of $25.96.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, August 9th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.04). The firm had revenue of $62.31 million for the quarter, compared to the consensus estimate of $68.49 million. Corcept Therapeutics had a net margin of 68.32% and a return on equity of 38.53%. The firm’s revenue was up 75.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.13 earnings per share. On average, equities analysts expect that Corcept Therapeutics will post 0.6 EPS for the current fiscal year.

In related news, Director G Leonard Baker, Jr. purchased 179,686 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was bought at an average cost of $12.48 per share, for a total transaction of $2,242,481.28. Following the completion of the transaction, the director now directly owns 876,838 shares in the company, valued at $10,942,938.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $13.19, for a total value of $105,520.00. Following the completion of the sale, the insider now owns 8,000 shares of the company’s stock, valued at $105,520. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 321,159 shares of company stock valued at $4,025,880 and sold 24,000 shares valued at $335,280. 15.00% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Asset Management One Co. Ltd. bought a new stake in shares of Corcept Therapeutics during the first quarter worth $150,000. Stifel Financial Corp bought a new stake in shares of Corcept Therapeutics during the first quarter worth $182,000. Fox Run Management L.L.C. bought a new stake in shares of Corcept Therapeutics during the third quarter worth $211,000. Engineers Gate Manager LP bought a new stake in shares of Corcept Therapeutics during the second quarter worth $213,000. Finally, Stevens Capital Management LP bought a new stake in shares of Corcept Therapeutics during the second quarter worth $214,000. Institutional investors own 74.78% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Featured Story: Trading Strategy Examples and Plans

Analyst Recommendations for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.